Op-qjec160023 1681..1726
نویسندگان
چکیده
We study the drivers of geographic variation in U.S. health care utilization, using an empirical strategy that exploits migration of Medicare patients to separate the role of demand and supply factors. Our approach allows us to account for demand differences driven by both observable and unobservable patient characteristics. Within our sample of over-65 Medicare beneficiaries, we find that 40–50% of geographic variation in utilization is attributable to demand-side factors, including health and preferences, with the remainder due to place-specific supply factors. JEL Codes: H51, I1, I11.
منابع مشابه
Energy Requirements of Using Oil Shale in the Production of Ordinary Portland Clinker
Energy balance was performed on the clinkering process when utilizing oil shale as a source of both raw materials and energy. The balance was also compared with the typical energy requirements for production of Ordinary Portland (OP) Clinker. The use of Jordanian oil shale can reduce energy requirements in production of OP clinker by 15–20%. This reduction is due to two factors: lower clinkerin...
متن کاملشناسایی نشانگرهای مولکولی پیوسته با ژن(های) مقاومت به نماتد مولد سیست چغندرقند
با توجه به اهمیت وگستردگی نماتد مولد سیست چغندرقند (Heterodera schachtii Schmidt) در جهان و به منظور جلوگیری از کاهش قابل توجه محصول ریشه و قند ناشی از این نماتد تلاشهای زیادی صورت میگیرد و مناسبترین روش مدیریت آن اصلاح ارقام مقاوم میباشد. گونههای وحشی گروهprocumbentes در جنسBeta بهدلیل داشتن ژنهای مقاومت به بیماریهای مختلف چغندرقند ازجمله مقاومت به نماتد اهمیت زیادی دارند. برای شناسا...
متن کاملTherapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis.
BACKGROUND Leflunomide is the prodrug of the disease modifying antirheumatic metabolite A77 1726. More than 50% of patients withdraw from leflunomide treatment within one year, mainly because of adverse drug reactions. Therapeutic drug monitoring of A77 1726 may be useful in predicting the efficacy of leflunomide treatment. OBJECTIVE To study the relation between A77 1726 steady state serum c...
متن کاملInhibition of p70 S6 Kinase (S6K1) Activity by A77 1726 and Its Effect on Cell Proliferation and Cell Cycle Progress12
Leflunomide is a novel immunomodulatory drug prescribed for treating rheumatoid arthritis. It inhibits the activity of protein tyrosine kinases and dihydroorotate dehydrogenase, a rate-limiting enzyme in the pyrimidine nucleotide synthesis pathway. Here, we report that A77 1726, the active metabolite of leflunomide, inhibited the phosphorylation of ribosomal protein S6 and two other substrates ...
متن کاملThe active metabolite of leflunomide, A77 1726, increases the production of IL-1 receptor antagonist in human synovial fibroblasts and articular chondrocytes
Leflunomide is an immunomodulatory agent used for the treatment of rheumatoid arthritis. In this study, we investigated the effect of A77 1726 - the active metabolite of leflunomide - on the production of IL-1 receptor antagonist (IL-1Ra) by human synovial fibroblasts and articular chondrocytes. Cells were incubated with A77 1726 alone or in combination with proinflammatory cytokines. IL-1Ra pr...
متن کامل